시장보고서

상품코드

1493175

임상시험 관리 시스템 시장 규모, 점유율, 동향 분석 보고서 : 솔루션 유형별, 제공 모드별, 구성요소별, 최종사용자별, 지역별, 부문별 예측(2024-2030년)

Clinical Trials Management System Market Size, Share & Trends Analysis Report By Solution Type, By Delivery Mode (Web & Cloud-based, On-premise), By Component (Software, Services), By End-user, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 05월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

임상시험 관리 시스템 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 임상시험 관리 시스템 시장 규모는 2030년까지 47억 3,000만 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 14.65% 성장할 것으로 예상됩니다.

임상시험 건수 증가, 가상 임상시험 및 분산형 임상시험의 증가, eClinical 솔루션에 대한 수요 증가 등이 시장 성장의 요인으로 작용하고 있습니다.

생명과학 기업의 R&D 투자 증가와 급성 및 만성 질환의 유행으로 인해 환자 치료 결과를 개선하기 위한 임상시험이 급증하고 있습니다. 예를 들어, ClinicalTrials.gov에 보고된 당뇨병 관련 유효 임상시험은 653건으로, 여러 임상시험을 효율적으로 관리할 수 있는 임상시험 관리(CTM) 시스템과 같은 솔루션에 대한 수요가 높다는 것을 알 수 있습니다.

여러 시장 기업들이 DCT와 그 요구사항에 맞춰 맞춤형 솔루션을 출시하거나 기존 솔루션을 최적화하고 있습니다. 예를 들어, Cloudbyz의 분산형 CTM 솔루션은 ePRO, 원격 모니터링 및 SDV, eConsent, eCRF, EDC, eCOA, eDiary, 가상 PR, eTMF 등 다양한 기능을 제공하는 클라우드 기반 CTM 솔루션으로, 가상 시험을 지원합니다. 2022년 현재 이 시장의 선두주자인 Parexel International Corporation은 250건 이상의 완전 가상 또는 하이브리드 DCT를 수행했으며, 200건 이상의 원격 환자 참여 전략(환자 모집, e-visits, 리텐션 플랫폼 등)을 임상시험에 통합한 경험이 있습니다.

임상시험 관리 시스템 시장 보고서 하이라이트

헬스케어 IT의 급격한 성장, 임상시험 수 증가, CTMS 솔루션 도입 확대, 선진국과 신흥국 모두 임상연구에 대한 정부 지원 등이 시장을 주도하고 있습니다.
솔루션 유형별로는 엔터프라이즈 부문이 2023년 74.35%로 가장 큰 매출 점유율을 차지하며 시장을 주도했습니다. 주요 이점으로는 편차 및 미수금에 대한 엔드투엔드 인사이트 제공, 강력한 보고, 솔루션의 확장성, 규제 프로세스 추적 및 관리, 청구 규정 준수 강화 등이 있습니다.
구성요소별로는 소프트웨어 부문이 2023년 56.04%의 최대 매출 점유율로 시장을 주도했습니다. 이는 임상시험을 관리하고 중요한 기능을 수행하는 데 도움이 되는 사용하기 쉬운 도구이기 때문입니다.
제공 형태별로는 웹 & 클라우드 분야가 2023년 56.04%의 최대 매출 점유율로 시장을 주도했습니다.
최종 용도별로는 CRO 및 기타 부문이 제휴 증가, CRO로의 임상시험 아웃소싱, 임상시험 수의 분산으로 인해 2023년 40.16%의 가장 큰 매출 점유율을 차지했습니다.
북미는 2023년 50.01%의 매출 점유율로 시장을 장악했는데, 이는 기술 발전, 이 지역 시장 기업의 강력한 존재감, 임상시험 분야의 기술 발전, 임상시험을 촉진하기 위한 정부 지원 정책 덕분입니다.

주요 시장 진출 기업에 의한 최근의 동향과 영향 분석
기업/경쟁 분류
- 이노베이터
벤더 상황
- 주요 유통업체 및 채널 파트너 리스트
- 주요 고객
- 주요 기업의 시장 점유율 분석, 2023년
- IQVIA, Inc.
- Medidata(Dassault Systemes)
- Oracle
- DATATRAK International, Inc.
- Clario
- SimpleTrials
- Calyx(formerly Parexel Informatics)
- RealTime Software Solutions, LLC
- Laboratory Corporation of America Holdings
- Veeva Systems
- Wipro Limited
- PHARMASEAL International Ltd

ksm 24.06.18

Clinical Trials Management System Market Growth & Trends:

The global clinical trials management system market size is anticipated to reach USD 4.73 billion by 2030 and is projected to grow at a CAGR of 14.65% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing number of clinical trials, a rise in virtual or decentralized clinical trials, and the growing demand for eClinical solutions are some of the factors contributing to the market growth.

Life science companies' rising R&D investments and the prevalence of acute and chronic disorders contribute to the surge in clinical trials aimed at enhancing patient outcomes. For instance, ClinicalTrials.gov reports 653 active clinical trials on diabetes, indicating a significant demand for solutions like Clinical Trial Management (CTM) systems to efficiently manage multiple trials.

Several market players are launching tailored solutions or optimizing existing solutions to fit DCTs and their requirements. For example, the decentralized CTM Solution by Cloudbyz offers a cloud-based CTM solution that offers a range of features such as ePRO, remote monitoring & SDV, eConsent, eCRF, EDC, eCOA, eDiary, virtual PR, and eTMF to support virtual trials. As of 2022, Parexel International Corporation, a key player in the market, conducted over 250 fully virtual or hybrid DCTs and has experience with over 200 remote patient engagement strategies, e.g., patient recruitment, e-visits, and retention platforms, incorporated into trials.

Clinical Trials Management System Market Report Highlights:

The market is primarily driven by rapid growth of healthcare IT, rise in the number of clinical trials, increased adoption of CTMS solutions, and government support for clinical research in both developed & developing countries
Based on solution type, the enterprise segment led the market with the largest revenue share of 74.35% in 2023, owing to its key benefits, such as offering end-to-end insights into deviations & accruals, robust reporting, scalability of solutions, tracking & managing regulatory processes, and enhanced billing compliance
Based on component, the software segment led the market with the largest revenue share of 56.04% in 2023, due to it being an easy-to-use tool that helps manage clinical trials and perform critical functions
Based on delivery mode, web & cloud segment led the market with the largest revenue share of 56.04% in 2023, due to its increased adoption by end users
Based on end user, the CRO and others segment held the market with the largest revenue share of 40.16% in 2023, owing to the increasing number of partnerships, clinical trial outsourcing to CROs, and decentralized trial counts
North America dominated the market with a revenue share of 50.01% in 2023, owing to the technological advancements, strong presence of market players in the regions, technological advancement in the field of clinical trials, and supportive government policies to promote clinical trials

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Solution Type
- 1.1.2. Component
- 1.1.3. Delivery mode
- 1.1.4. End user
- 1.1.5. Regional scope
- 1.1.6. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
1.4. Information or Data Analysis
- 1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.2. Approach 1: Commodity flow approach
- 1.6.3. Volume price analysis (Model 2)
- 1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Solution type outlook
- 2.2.2. Component outlook
- 2.2.3. Delivery mode outlook
- 2.2.4. End user outlook
- 2.2.5. Regional outlook
2.3. Competitive Insights

Chapter 3. Clinical Trials Management System Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Clinical Trials Management System Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Economic landscape
  - 3.3.2.3. Social landscape
  - 3.3.2.4. Technological landscape
  - 3.3.2.5. Environmental landscape
  - 3.3.2.6. Legal landscape

Chapter 4. Clinical Trials Management System Market: Solution Type Estimates & Trend Analysis

4.1. Solution Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Clinical Trials Management System Market, by Solution Type Outlook
4.4. Descriptive Analysis
- 4.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
4.5. Enterprise
- 4.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
4.6. Site
- 4.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 5. Clinical Trials Management System Market: Component Estimates & Trend Analysis

5.1. Component Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Clinical Trials Management System Market, by Component Outlook
5.4. Software
- 5.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
5.5. Services
- 5.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 6. Clinical Trials Management System Market: Delivery Mode Estimates & Trend Analysis

6.1. Delivery Modes Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Clinical Trials Management System Market, by Delivery Modes Outlook
6.4. On-Premises
- 6.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
6.5. Web & Cloud-Based
- 6.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 7. Clinical Trials Management System Market: End-user Estimates & Trend Analysis

7.1. Application Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Clinical Trials Management System Market by Application Outlook
7.4. Pharmaceutical and Biotechnology Firms
- 7.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
7.5. Medical Device Firms
- 7.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
7.6. CROs & Others
- 7.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 8. Clinical Trials Management System Market: Regional Estimates & Trend Analysis, By Solution Type, By Component, By Delivery Mode, By End Use

8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
8.5. North America
- 8.5.1. U.S.
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Regulatory framework/ reimbursement structure
  - 8.5.1.3. Competitive scenario
  - 8.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.5.2. Canada
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework/ reimbursement structure
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
8.6. Europe
- 8.6.1. UK
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Regulatory framework/ reimbursement structure
  - 8.6.1.3. Competitive scenario
  - 8.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.2. Germany
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework/ reimbursement structure
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.3. France
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Regulatory framework/ reimbursement structure
  - 8.6.3.3. Competitive scenario
  - 8.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.4. Italy
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Regulatory framework/ reimbursement structure
  - 8.6.4.3. Competitive scenario
  - 8.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.5. Spain
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Regulatory framework/ reimbursement structure
  - 8.6.5.3. Competitive scenario
  - 8.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.6. Denmark
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Regulatory framework/ reimbursement structure
  - 8.6.6.3. Competitive scenario
  - 8.6.6.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.7. Sweden
  - 8.6.7.1. Key country dynamics
  - 8.6.7.2. Regulatory framework/ reimbursement structure
  - 8.6.7.3. Competitive scenario
  - 8.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.8. Norway
  - 8.6.8.1. Key country dynamics
  - 8.6.8.2. Regulatory framework/ reimbursement structure
  - 8.6.8.3. Competitive scenario
  - 8.6.8.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
8.7. Asia Pacific
- 8.7.1. Japan
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Regulatory framework/ reimbursement structure
  - 8.7.1.3. Competitive scenario
  - 8.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.7.2. China
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework/ reimbursement structure
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.7.3. India
  - 8.7.3.1. Key country dynamics
  - 8.7.3.2. Regulatory framework/ reimbursement structure
  - 8.7.3.3. Competitive scenario
  - 8.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.7.4. Australia
  - 8.7.4.1. Key country dynamics
  - 8.7.4.2. Regulatory framework/ reimbursement structure
  - 8.7.4.3. Competitive scenario
  - 8.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.7.5. South Korea
  - 8.7.5.1. Key country dynamics
  - 8.7.5.2. Regulatory framework/ reimbursement structure
  - 8.7.5.3. Competitive scenario
  - 8.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.7.6. Thailand
  - 8.7.6.1. Key country dynamics
  - 8.7.6.2. Regulatory framework/ reimbursement structure
  - 8.7.6.3. Competitive scenario
  - 8.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
8.8. Latin America
- 8.8.1. Brazil
  - 8.8.1.1. Key country dynamics
  - 8.8.1.2. Regulatory framework/ reimbursement structure
  - 8.8.1.3. Competitive scenario
  - 8.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.8.2. Mexico
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Regulatory framework/ reimbursement structure
  - 8.8.2.3. Competitive scenario
  - 8.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.8.3. Argentina
  - 8.8.3.1. Key country dynamics
  - 8.8.3.2. Regulatory framework/ reimbursement structure
  - 8.8.3.3. Competitive scenario
  - 8.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
8.9. MEA
- 8.9.1. South Africa
  - 8.9.1.1. Key country dynamics
  - 8.9.1.2. Regulatory framework/ reimbursement structure
  - 8.9.1.3. Competitive scenario
  - 8.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.9.2. Saudi Arabia
  - 8.9.2.1. Key country dynamics
  - 8.9.2.2. Regulatory framework/ reimbursement structure
  - 8.9.2.3. Competitive scenario
  - 8.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.9.3. UAE
  - 8.9.3.1. Key country dynamics
  - 8.9.3.2. Regulatory framework/ reimbursement structure
  - 8.9.3.3. Competitive scenario
  - 8.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.9.4. Kuwait
  - 8.9.4.1. Key country dynamics
  - 8.9.4.2. Regulatory framework/ reimbursement structure
  - 8.9.4.3. Competitive scenario
  - 8.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
- 9.2.1. Innovators
9.3. Vendor Landscape
- 9.3.1. List of key distributors and channel partners
- 9.3.2. Key customers
- 9.3.3. Key company market share analysis, 2023
- 9.3.4. IQVIA, Inc.
  - 9.3.4.1. Company overview
  - 9.3.4.2. Financial performance
  - 9.3.4.3. Product benchmarking
  - 9.3.4.4. Strategic initiatives
- 9.3.5. Medidata (Dassault Systemes)
  - 9.3.5.1. Company overview
  - 9.3.5.2. Financial performance
  - 9.3.5.3. Product benchmarking
  - 9.3.5.4. Strategic initiatives
- 9.3.6. Oracle
  - 9.3.6.1. Company overview
  - 9.3.6.2. Financial performance
  - 9.3.6.3. Product benchmarking
  - 9.3.6.4. Strategic initiatives
- 9.3.7. DATATRAK International, Inc.
  - 9.3.7.1. Company overview
  - 9.3.7.2. Financial performance
  - 9.3.7.3. Product benchmarking
  - 9.3.7.4. Strategic initiatives
- 9.3.8. Clario
  - 9.3.8.1. Company overview
  - 9.3.8.2. Financial performance
  - 9.3.8.3. Product benchmarking
  - 9.3.8.4. Strategic initiatives
- 9.3.9. SimpleTrials
  - 9.3.9.1. Company overview
  - 9.3.9.2. Financial performance
  - 9.3.9.3. Product benchmarking
  - 9.3.9.4. Strategic initiatives
- 9.3.10. Calyx (formerly Parexel Informatics)
  - 9.3.10.1. Company overview
  - 9.3.10.2. Financial performance
  - 9.3.10.3. Product benchmarking
  - 9.3.10.4. Strategic initiatives
- 9.3.11. RealTime Software Solutions, LLC
  - 9.3.11.1. Company overview
  - 9.3.11.2. Financial performance
  - 9.3.11.3. Product benchmarking
  - 9.3.11.4. Strategic initiatives
- 9.3.12. Laboratory Corporation of America Holdings
  - 9.3.12.1. Company overview
  - 9.3.12.2. Financial performance
  - 9.3.12.3. Product benchmarking
  - 9.3.12.4. Strategic initiatives
- 9.3.13. Veeva Systems
  - 9.3.13.1. Company overview
  - 9.3.13.2. Financial performance
  - 9.3.13.3. Product benchmarking
  - 9.3.13.4. Strategic initiatives
- 9.3.14. Wipro Limited
  - 9.3.14.1. Company overview
  - 9.3.14.2. Financial performance
  - 9.3.14.3. Product benchmarking
  - 9.3.14.4. Strategic initiatives
- 9.3.15. PHARMASEAL International Ltd
  - 9.3.15.1. Company overview
  - 9.3.15.2. Financial performance
  - 9.3.15.3. Product benchmarking
  - 9.3.15.4. Strategic initiatives

임상시험 관리 시스템 시장 규모, 점유율, 동향 분석 보고서 : 솔루션 유형별, 제공 모드별, 구성요소별, 최종사용자별, 지역별, 부문별 예측(2024-2030년)

Clinical Trials Management System Market Size, Share & Trends Analysis Report By Solution Type, By Delivery Mode (Web & Cloud-based, On-premise), By Component (Software, Services), By End-user, By Region, And Segment Forecasts, 2024 - 2030

임상시험 관리 시스템 시장 성장과 동향:

임상시험 관리 시스템 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 임상시험 관리 시스템 시장 변수, 동향, 범위

제4장 임상시험 관리 시스템 시장 : 솔루션 유형 추정·동향 분석

제5장 임상시험 관리 시스템 시장 : 컴포넌트 추정·동향 분석

제6장 임상시험 관리 시스템 시장 : 제공 모드 추정·동향 분석

제7장 임상시험 관리 시스템 시장 : 최종사용자 추정·동향 분석

제8장 임상시험 관리 시스템 시장 : 지역 추정·동향 분석, 솔루션 유형별, 컴포넌트별, 배포 방식별, 최종 용도별

제9장 경쟁 상황